AAAndrij Abramyuk

Andrij Abramyuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrij Abramyuk has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis—an animal experimental prospective cohort study

    by Martin Mirus, Sergey V. Tokalov, Andrij Abramyuk, Jessica Heinold, Vincent Prochnow, Klaus Zöphel, Jörg Kotzerke, Nasreddin Abolmaali

    This study investigated the noninvasive assessment of tumor vascularization with clinical F-18-fluorodeoxyglucose positron emission tomography/computed tomography and contrast-enhanced computed tomography ([18F]FDG-PET/CT and CE-CT) in experimental human xenograft tumors with modifiable vascularization and compared results to histology. Tumor xenografts with modifiable vascularization were established in 71 athymic nude rats by subcutaneous transplantation of human non-small-cell lung cancer (NSCLC) cells. Four different groups were transplanted with two different tumor cell lines (either A549 or H1299) alone or tumors co-transplanted with rat glomerular endothelial (RGE) cells, the latter to increase vascularization. Tumors were assessed noninvasively by [18F]FDG PET/CT and contrast-enhanced CT (CE-CT) using clinical scanners. This was followed by histological examinations evaluating tumor vasculature (CD-31 and intravascular fluorescent beads). In both tumor lines (A549 and H1299), co-transplantation of RGE cells resulted in faster growth rates [maximal tumor diameter of 20 mm after 22 (± 1.2) as compared to 45 (± 1.8) days, p < 0.001], higher microvessel density (MVD) determined histologically after CD-31 staining [171.4 (± 18.9) as compared to 110.8 (± 11) vessels per mm2, p = 0.002], and higher perfusion as indicated by the number of beads [1.3 (± 0.1) as compared to 1.1 (± 0.04) beads per field of view, p = 0.001]. In [18F]FDG-PET/CT, co-transplanted tumors revealed significantly higher standardized uptake values [SUVmax, 2.8 (± 0.2) as compared to 1.1 (± 0.1), p < 0.001] and larger metabolic active volumes [2.4 (± 0.2) as compared to 0.4 (± 0.2) cm3, p < 0.001] than non-co-transplanted tumors. There were significant correlations for vascularization parameters derived from histology and [18F]FDG PET/CT [beads and SUVmax, r = 0.353, p = 0.005; CD-31 and SUVmax, r = 0.294, p = 0.036] as well as between CE-CT and [18F]FDG PET/CT [contrast enhancement and SUVmax, r = 0.63, p < 0.001; vital CT tumor volume and metabolic PET tumor volume, r = 0.919, p < 0.001]. In this study, a human xenograft tumor model with modifiable vascularization implementable for imaging, pharmacological, and radiation therapy studies was successfully established. Both [18F]FDG-PET/CT and CE-CT are capable to detect parameters closely connected to the degree of tumor vascularization, thus they can help to evaluate vascularization in tumors noninvasively. [18F]FDG-PET may be considered for characterization of tumors beyond pure glucose metabolism and have much greater contribution to diagnostics in oncology.


  • Telemedical Brain Computed Tomography Misinterpretation by Stroke Neurologists Is Not Associated with Thrombolysis-Related Intracranial Hemorrhage

    by Charlotte Zerna, Ruediger von Kummer, Johannes Gerber, Kai Engellandt, Andrij Abramyuk, Claudia Wojciechowski, Kristian Barlinn, Jessica Kepplinger, Lars-Peder Pallesen, Timo Siepmann, et al.


  • Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours

    by A Abramyuk, V Hietschold, S Appold, R von Kummer, N Abolmaali

    To investigate radiochemotherapy (RChT)-induced changes of transfer coefficient (K(trans)) and relative tumour blood volume (rTBV) estimated by dynamic contrast-enhanced CT (DCE-CT) and fractal analysis in head and neck tumours (HNTs). DCE-CT was performed in 15 patients with inoperable HNTs before RChT, and after 2 and 5 weeks. The dynamics of K(trans) and rTBV as well as lacunarity, slope of log(lacunarity) vs log(box size), and fractal dimension were compared with tumour behaviour during RChT and in the 24-month follow-up. In 11 patients, an increase of K(trans) and/or rTBV after 20 Gy followed by a decrease of both parameters after 50 Gy was noted. Except for one local recurrence, no tumour residue was found during the follow-up. In three patients with partial tumour reduction during RChT, a decrease of K(trans) accompanied by an increase in rTBV between 20 and 50 Gy was detected. In one patient with continuous elevation of both parameters, tumour progressed after RChT. Pre-treatment difference in intratumoral heterogeneity with its decline under RChT for the responders vs non-responders was observed. Initial growth of K(trans) and/or rTBV followed by further reduction of both parameters along with the decline of the slope of log(lacunarity) vs log(box size) was associated with positive radiochemotherapeutic response. Increase of K(trans) and/or rTBV under RChT indicated a poor outcome. The modification of K(trans) and rTBV as measured by DCE-CT may be applied for the assessment of tumour sensitivity to chose RChT regimen and, consequently, to reveal clinical impact allowing individualization of RChT strategy in patients with HNT.


  • Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy

    by A. Abramyuk, S. Appold, K. Zöphel, M. Baumann, N. Abolmaali

    Reliable tumor staging is a fundamental pre-requisite for efficient tumor therapy and further prognosis. The aim of this study was to compare head and neck cancer (HNC) staging before and after FDG-PET/CT, evaluating the stage modifications for radiotherapy (RT) planning. A total of 102 patients with untreated primary HNC, who underwent conventional staging and staging including FDG-PET/CT before RT, were enrolled in this retrospective study. Blinded pre-FDG-PET/CT and post-FDG-PET/CT staging data were compared. The impact on patient management was tested by comparing the intention before and after FDG-PET/CT. Significant modifications of T, N, and M stage as well as clinical stage were detected after inclusion of FDG-PET/CT data (p = 0.002, 0.0006, 0.001, 0.03, respectively). Overall, the implementation of FDG-PET/CT led to modification of RT intention decision in 14 patients. FDG-PET/CT demonstrates essential influence on tumor staging in HNC patients scheduled for irradiation. Implementation of FDG-PET/CT in imaging protocol improves selection of candidates for curative and palliative RT and allows further optimization of treatment management and therapy intention. Ein zuverlässiges Staging ist ausschlaggebend für eine optimale Tumortherapie und die weitere Prognose. Die Studie sollte klären, ob die Einbeziehung der FDG-PET/CT in die Diagnostik von Patienten mit Kopf-Hals-Tumoren (KHT) vor Strahlentherapie das TNM-, das klinische Staging und die Therapieintention im Vergleich zum konventionellen Staging verändert. 102 konsekutive Patienten mit unbehandelten Kopf-Hals-Tumoren (KHT) erhielten nach dem klinischen Standardstaging, anhand dessen eine Strahlentherapie geplant worden wäre, ergänzend eine FDG-PET/CT. Es wurden die Staging-Daten vor und nach FDG-PET/CT verglichen und der Einfluss auf das Patientenmanagement durch den Vergleich der Therapieplanung vor und nach FDG-PET/CT untersucht. Die Berücksichtigung der FDG-PET/CT-Daten führte zur einer signifikanten Änderung der T-, N-, M-Stadien (p = 0,002; 0,0006; 0,001) sowie des klinischen Stadiums (p=0,03). Insgesamt wurde bei 14 Patienten eine Modifikation der Strahlentherapieintention festgestellt. Der Einsatz der FDG-PET/CT bei Patienten mit Kopf-Hals-Tumoren vor Strahlentherapie ermöglicht eine verfeinerte Auswahl der Kandidaten für kurative und palliative Bestrahlung und führt im Vergleich zum konventionellen Staging zu einer verbesserten Therapieentscheidung.


  • Anwendung fraktaler Analyse auf DCE-CT-Daten zur Bestimmung der antivaskulären Wirkung der kombinierten Radiochemotherapie auf Kopf-Hals-Tumoren

    by A Abramyuk, V Hietschold, K Zöphel, S Appold, M Baumann, R von Kummer, N Abolmaali

    Ziele: Es gibt Hinweise, dass Radiochemotherapie (RCT) neben unmittelbarer antitumoraler Wirkung auch einen modifizierenden Effekt auf die Tumorangiogenese hat. Ziel der Arbeit war die Bestimmung von RCT-induzierten Duchblutungsveränderungen in Kopf-Hals-Tumoren (KHT) mittels DCE-CT und fraktaler Analyse. Methode: DCE-CT wurde bei 15 Patienten mit klinisch inoperablen KHT vor RCT, nach 2 Wochen (20Gy/3 Zyklen Cisplatin+1 Zyklus 5-Fluorouracil) sowie nach 5 Wochen (50Gy/5 Zyklen Cisplatin + 1 Zyklus 5-Fluorouracil) mittels PET-CT (Biograph 16, Siemens) durchgeführt. Die Transferkonstante (Ktrans) wurde anhand der Patlak-Analyse mit VPCT-Software (Siemens) bestimmt. Intratumorale Inhomogenitätsparameter Lakunarität und DB (Anstieg ln (Lakunarität) von ln (Boxgröße)) wurden von den Ktrans-Maps mit dem Sliding-Box-Algorithmus berechnet. Zusätzlich wurde die Dynamik von DCE-CT-Parametern mit der Änderung der Tumorgröße unter RCT verglichen. Mittlere follow-up Zeit war 12 Monate. Ergebnis: Bei 11 Patienten ergab sich eine Steigerung des Ktrans nach 20Gy mit folgender Absenkung nach 50Gy (pSchlussfolgerung: Veränderungen der absoluten Werte des Ktrans sowie seines intratumoralen Verteilungsmusters weisen auf eine Modifizierung der lokalen Tumordurchblutung unter RCT in KHT hin. Es ist lohnenswert, in einer prospektiven Studie zu untersuchen, ob die simultane Bestimmung von Ktrans und der Lakunarität bzw. DB zum Therapiemonitoring von KHT eingesetzt werden kann. Keywords: Fraktale Analyse, DCE-CT, Radiochemotherapie, Kopf-Hals-Tumoren, Durchblutung Korrespondierender Autor: Abramyuk A Institut und Poliklinik für Radiologische Diagnostik, Neuroradiologie, Fetscherstr. 74, 01307 Dresden E-Mail: Andrij.Abramyuk@uniklinikum-dresden.de